RxDoctor Payments Data

Karen Memoli, OD

Optometrist · North Port, FLNPI 1508965104

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 44 payments — averaging $54.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$692
  • Johnson & Johnson Surgical Vision, Inc.$357
  • Tarsus Pharmaceuticals, Inc.$279
  • Ocular Therapeutix, Inc.$235
  • Sun Pharmaceutical Industries Inc.$225
  • Johnson & Johnson Vision Care, Inc.$138
  • plus $478 from 7 others

What the payments were for

  • Speaking & faculty fees$51421%
  • Food & beverage$1,89279%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,405 in reported general payments places this provider in the 75th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$152,276
Medicare patients
857
Services billed
1,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine16$20,024
LumiganBimatoprost31$17,749
VyzultaLatanoprostene Bunod26$16,950
MieboPerfluorohexyloctane/Pf20$16,324
Latanoprost513$7,412
Travoprost14$3,927
Alphagan PBrimonidine Tartrate14$3,096
Prednisolone Acetate104$2,757
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat75$1,748
Brimonidine Tartrate75$1,038
Timolol Maleate137$961
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha72$732
Dorzolamide Hcl40$698
Doxycycline Hyclate21$685
ValacyclovirValacyclovir Hcl12$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$45$33,27546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,166 optometrist providers in Florida.

Other optometrist in North Port

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →